我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
32
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
24
75.0%
招募中
8
25.0%
暂无批准数据
- Restore Vision Inc. has initiated the world's first clinical trial of optogenetic gene therapy using "Chimeric Rhodopsin" technology for treating retinitis pigmentosa patients. - The Phase I/II trial commenced at Keio University Hospital, utilizing RV-001, an AAV-vector-delivered gene therapy administered through intravitreal injection to restore light sensitivity. - The innovative gene-agnostic approach targets over 2 million people worldwide affected by retinitis pigmentosa, offering potential treatment regardless of genetic subtype.
